Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707859 | 0.86 | CAPN1 (0.66) | CAPN1 | |
| SCHEMBL21707884 | 0.81 | CAPN1 (0.74) | CAPN1GPR84ESR1ESR2 | |
| SCHEMBL20204597 | 0.81 | CAPN1 (0.55) | CAPN1GPR84 | |
| SCHEMBL16431613 | 0.79 | DAO (0.42) | CAPN1GPR84PDE3BPDE3A | |
| SCHEMBL21707855 | 0.74 | CAPN1 (0.53) | CAPN1GPR84ESR1ESR2 | |
| SCHEMBL20204711 | 0.70 | CAPN1 (0.63) | CAPN1TAAR1 | |
| SCHEMBL21707860 | 0.70 | AHR (0.48) | CAPN1GPR84SLC6A2 | |
| SCHEMBL21707862 | 0.69 | CAPN1 (0.61) | CAPN1TAAR1 | |
| SCHEMBL29884027 | 0.68 | HRH2 (0.45) | CAPN1 | |
| SCHEMBL10567513 | 0.68 | ESR1 (0.45) | CAPN1ESR1ESR2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852341-A | Cyclic dipeptide compound with pyrazinone ring, and preparation method and application thereof | 南京大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20240294581-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF | UNIV YALE (US) | 2024-09-05 | — | — | US | disclosed |
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | YALE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | LPXN, LAP3, PEPD | CAPN1 895/4885GPR84 4124/4885ESR1 1014/4885 |
| US-20240294581-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF | LPXN, LAP3, PEPD | CAPN1 1044/4885GPR84 4104/4885ESR1 1064/4885 |
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CAPN1 81/4885GPR84 3992/4885ESR1 1853/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CAPN1 81/4885GPR84 3992/4885ESR1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.